Eden Biodesign and Borean Pharma ApS sign deal to develop novel therapeutic candidate for the treatment of cancer
Eden Biodesign Ltd and Borean Pharma ApS announced that they have signed an agreement under which Eden will manufacture MBP-DC-SIGN, a novel therapeutic candidate for the treatment of a range of cancers, for Borean to use in key preclinical studies. The project is expected to complete early in 2008.
MBP-DC-SIGN is one of Borean's products to be based on the Mannose-Binding protein (MBP) platform. The MBP platform is delivering a series of highly potent therapeutics for the treatment of cancers, and is the only scaffold that can induce complement-induced lysis.
The agreement with Borean Pharma is the fourth contract to be announced by Eden Biodesign in the past 7 weeks, following announcements for cGMP manufacturing and development projects with CRUK, University of Birmingham and UMIP.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.